Reply: Statins for the prevention of cirrhosis complications: An American emulation of the StatLiver trial.
作者信息
Kimer Nina, Kronborg Thit M, Bendtsen Flemming
机构信息
Gastro Unit, Medical Division, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
出版信息
Hepatol Commun. 2024 Oct 30;8(11). doi: 10.1097/HC9.0000000000000551. eCollection 2024 Nov 1.
Abstract
摘要
相似文献
1
Reply: Statins for the prevention of cirrhosis complications: An American emulation of the StatLiver trial.回复：他汀类药物预防肝硬化并发症：美国对StatLiver试验的效仿。
Hepatol Commun. 2024 Oct 30;8(11). doi: 10.1097/HC9.0000000000000551. eCollection 2024 Nov 1.
2
Statins for the prevention of cirrhosis complications: An American emulation of the StatLiver Trial.他汀类药物预防肝硬化并发症：美国对StatLiver试验的效仿。
Hepatol Commun. 2024 Sep 18;8(10). doi: 10.1097/HC9.0000000000000530. eCollection 2024 Oct 1.
3
Addition of statins to the standard treatment in patients with cirrhosis: Safety and efficacy.在肝硬化患者的标准治疗中添加他汀类药物：安全性和疗效。
World J Gastroenterol. 2021 Jul 28;27(28):4639-4652. doi: 10.3748/wjg.v27.i28.4639.
4
Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects.他汀类药物在慢性肝病和肝硬化患者中的应用：当前观点与前景
Curr Gastroenterol Rep. 2017 Sep;19(9):43. doi: 10.1007/s11894-017-0584-7.
5
Response to the letter titled reply to "Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US".对题为《司美格鲁肽与2型糖尿病患者首次诊断阿尔茨海默病的关联：利用美国全国性真实世界数据进行目标试验模拟》的信件的回复
Alzheimers Dement. 2025 Feb;21(2):e14611. doi: 10.1002/alz.14611.
6
Clinical trial emulation in nephrology.肾脏病学中的临床试验模拟
J Nephrol. 2025 Jan;38(1):11-23. doi: 10.1007/s40620-024-02158-5. Epub 2024 Nov 27.
7
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population-based observational data.长效纳曲酮与丁丙诺啡-纳洛酮在治疗中断方面的比较效果：对比X:BOT随机对照试验重新分析结果与使用基于人群的观察性数据进行的协调目标试验模拟结果。
Addiction. 2025 Aug;120(8):1634-1645. doi: 10.1111/add.70040. Epub 2025 Mar 19.
8
The Use of Statins in Patients With Chronic Liver Disease and Cirrhosis.他汀类药物在慢性肝病和肝硬化患者中的应用。
Curr Treat Options Gastroenterol. 2018 Jun;16(2):226-240. doi: 10.1007/s11938-018-0180-4.
9
SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation.SACRED：辛伐他汀对高危代偿性肝硬化患者肝失代偿和死亡的影响：他汀类药物与肝硬化：减少失代偿事件。
Contemp Clin Trials. 2021 May;104:106367. doi: 10.1016/j.cct.2021.106367. Epub 2021 Mar 24.
10
Long-Term Benefits and Safety of Statins in Patients with Kidney Failure: A Target Trial Emulation Study.他汀类药物对肾衰竭患者的长期益处及安全性：一项目标试验模拟研究
J Am Soc Nephrol. 2025 May 1;36(5):882-889. doi: 10.1681/ASN.0000000554. Epub 2024 Oct 31.
本文引用的文献
1
Statins for the prevention of cirrhosis complications: An American emulation of the StatLiver Trial.他汀类药物预防肝硬化并发症：美国对StatLiver试验的效仿。
Hepatol Commun. 2024 Sep 18;8(10). doi: 10.1097/HC9.0000000000000530. eCollection 2024 Oct 1.
2
Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial.阿托伐他汀治疗肝硬化患者：一项随机、安慰剂对照试验。
Hepatol Commun. 2023 Dec 1;7(12). doi: 10.1097/HC9.0000000000000332.
3
Effects of statins and aspirin on HCC risk in alcohol-related cirrhosis: nationwide emulated trials.他汀类药物和阿司匹林对酒精性肝硬化相关 HCC 风险的影响：全国模拟试验。
Hepatol Commun. 2023 Jan 3;7(1):e0013. doi: 10.1097/HC9.0000000000000013. eCollection 2023 Jan 1.
4
Baveno VII - Renewing consensus in portal hypertension.《巴韦诺 VII 共识：门静脉高压领域的新共识》
J Hepatol. 2022 Apr;76(4):959-974. doi: 10.1016/j.jhep.2021.12.022. Epub 2021 Dec 30.
5
Statins and the risks of decompensated liver cirrhosis and hepatocellular carcinoma determined in patients with alcohol use disorder.他汀类药物与酒精使用障碍患者失代偿性肝硬化和肝细胞癌风险的相关性研究。
Drug Alcohol Depend. 2021 Nov 1;228:109096. doi: 10.1016/j.drugalcdep.2021.109096. Epub 2021 Sep 20.
Zotero 插件